Notice: This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends PRTO vs. PROK, MGTX, KOD, ALLO, GLUE, PRME, AURA, TSHA, RGNX, and NMRAShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include ProKidney (PROK), MeiraGTx (MGTX), Kodiak Sciences (KOD), Allogene Therapeutics (ALLO), Monte Rosa Therapeutics (GLUE), Prime Medicine (PRME), Aura Biosciences (AURA), Taysha Gene Therapies (TSHA), REGENXBIO (RGNX), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector. Proteon Therapeutics vs. ProKidney MeiraGTx Kodiak Sciences Allogene Therapeutics Monte Rosa Therapeutics Prime Medicine Aura Biosciences Taysha Gene Therapies REGENXBIO Neumora Therapeutics ProKidney (NASDAQ:PROK) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk. Does the media favor PROK or PRTO? In the previous week, ProKidney had 8 more articles in the media than Proteon Therapeutics. MarketBeat recorded 8 mentions for ProKidney and 0 mentions for Proteon Therapeutics. ProKidney's average media sentiment score of 0.27 beat Proteon Therapeutics' score of 0.00 indicating that ProKidney is being referred to more favorably in the media. Company Overall Sentiment ProKidney Neutral Proteon Therapeutics Neutral Which has more risk and volatility, PROK or PRTO? ProKidney has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Which has higher earnings and valuation, PROK or PRTO? Proteon Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidneyN/AN/A-$35.47M-$0.55-3.33Proteon TherapeuticsN/AN/A-$20.73M-$1.15-5.09 Do institutionals & insiders believe in PROK or PRTO? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor PROK or PRTO? Proteon Therapeutics received 264 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 69.21% of users gave Proteon Therapeutics an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% Proteon TherapeuticsOutperform Votes27269.21% Underperform Votes12130.79% Do analysts recommend PROK or PRTO? ProKidney currently has a consensus target price of $4.50, suggesting a potential upside of 145.90%. Given ProKidney's stronger consensus rating and higher possible upside, equities research analysts plainly believe ProKidney is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PROK or PRTO more profitable? Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% Proteon Therapeutics N/A N/A -118.68% SummaryProKidney beats Proteon Therapeutics on 10 of the 14 factors compared between the two stocks. Ad StocksToTradeLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special offer before it’s too late. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.75M$3.01B$5.24B$9.01BDividend YieldN/A1.92%5.30%4.17%P/E Ratio-5.0946.1587.7217.25Price / SalesN/A332.361,083.85141.85Price / CashN/A182.3343.3337.89Price / Book-97.506.175.195.13Net Income-$20.73M-$41.49M$121.58M$227.03M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$5.85-4.7%N/A+195.2%$129.75MN/A-5.0917PROKProKidney2.2529 of 5 stars$1.81-2.7%$4.50+148.6%+24.0%$527.91MN/A-3.293News CoverageMGTXMeiraGTx3.8756 of 5 stars$6.34-1.2%$23.50+270.7%+0.6%$495.49M$13.93M-5.24300Positive NewsKODKodiak Sciences2.9626 of 5 stars$9.32+2.2%$8.00-14.2%+209.6%$490.46MN/A-2.5590ALLOAllogene Therapeutics2.8857 of 5 stars$2.16flat$9.73+350.6%-25.9%$452.89M$43,000.00-1.38310Positive NewsGLUEMonte Rosa Therapeutics2.9903 of 5 stars$6.89-3.9%$14.00+103.2%+24.7%$440.50M$14.98M-3.7790News CoveragePRMEPrime Medicine3.9356 of 5 stars$3.27-2.4%$12.67+287.4%-63.6%$428.90M$800,000.00-1.60234Analyst UpgradeAURAAura Biosciences2.6142 of 5 stars$8.22-2.7%$23.00+179.8%-7.1%$422.09MN/A-4.7550Positive NewsTSHATaysha Gene Therapies3.2455 of 5 stars$2.05+6.8%$6.63+223.2%+15.2%$420.13M$9.92M3.25180Analyst ForecastRGNXREGENXBIO4.6393 of 5 stars$8.19+5.4%$35.27+330.7%-50.2%$405.77M$84.33M-1.63344News CoveragePositive NewsNMRANeumora Therapeutics3.1975 of 5 stars$2.48+14.3%$16.50+565.3%-84.4%$400.67MN/A-1.33108Analyst ForecastOptions VolumeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies ProKidney Alternatives MeiraGTx Alternatives Kodiak Sciences Alternatives Allogene Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Prime Medicine Alternatives Aura Biosciences Alternatives Taysha Gene Therapies Alternatives REGENXBIO Alternatives Neumora Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRTO) was last updated on 1/7/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
